Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

ConclusionPatients with an e13a2 transcript demonstrate an inferior molecular response to imatinib in our regional population.
Source: BMC Hematology - Category: Hematology Source Type: research

Related Links:

AbstractThe distribution ofBCR –ABL1 transcript variants e13a2 ( “b2a2”) and e14a2 (“b3a2”) in Nigerians with chronic myeloid leukemia (CML) had not been previously studied. In addition, there is paucity of data on the impact ofBCR –ABL1 transcript variants on clinical presentation and survival in CML patients in Nigeria. TheBCR –ABL1 transcript variants were analyzed in 230 Imatinib-treated CML patients at diagnosis. Patients with incomplete data (n  = 28), e19a2 (n = 3) and e1a2 (n = 1) were excluded from analysis of transcript variant on...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Publication date: Available online 24 February 2020Source: Life SciencesAuthor(s): Fei-Yan Xiao, Zhi-Ping Jiang, Fang Yuan, Fang-Jiao Zhou, Wei Kuang, Gan Zhou, Xiao-Ping Chen, Rong Liu, Hong-Hao Zhou, Xie-Lan Zhao, Shan CaoAbstractBackgroundNQO1 protein acts as a cellular protective system, on account of its role as a quinone reductase and redox regulator. Nonetheless, new NQO1 roles are emerging—including its regulation of the cellular proliferation of many tumor cells—and this enzyme has been found to relate to the incidence of various diseases, including chronic myeloid leukemia. However, the mechanisms thr...
Source: Life Sciences - Category: Biology Source Type: research
Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Source: Clinical Chemistry and Laboratory Medicine - Category: Laboratory Medicine Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Leukemia, Published online: 20 February 2020; doi:10.1038/s41375-020-0771-7Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia
Source: Leukemia - Category: Hematology Authors: Source Type: research
AbstractPurpose of ReviewOral tyrosine kinase inhibitors have revolutionized the treatment of chronic myelogenous leukemia, with many patients achieving major clinical and molecular responses without complications. While typically well-tolerated, clinical experience with tyrosine kinase inhibitors (particularly those of the second and third generations) has highlighted unanticipated associations with serious non-cancer adverse effects on various organs, particularly the cardiovascular system.Recent FindingsHerein, we review the current literature surrounding the major cardiovascular toxicities of BCR-ABL1 tyrosine kinase i...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
Leukemia, Published online: 19 February 2020; doi:10.1038/s41375-020-0751-yAberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia
Source: Leukemia - Category: Hematology Authors: Source Type: research
PMID: 32081375 [PubMed - as supplied by publisher]
Source: Canadian Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Can J Ophthalmol Source Type: research
In conclusion, the results of the present study showed that the abrogation of PI3K using BKM120 might be a befitting approach in CML treatment, either as a single agent or in a combined-modal strategy; however, further evaluations including clinical trials and in vivo investigations are demanded to ascertain the safety and the efficacy of the inhibitor in treatment strategies. This article is protected by copyright. All rights reserved. PMID: 32068318 [PubMed - as supplied by publisher]
Source: Cell Biology International - Category: Cytology Authors: Tags: Cell Biol Int Source Type: research
T cell cancer neoantigens are created from peptides derived from cancer-specific aberrant proteins, such as mutated and fusion proteins, presented in complex with human leukocyte antigens on the cancer cell surface. Because expression of the aberrant target protein is exclusive to malignant cells, immunotherapy directed against neoantigens should avoid “on-target, off-tumor” toxicity. The efficacy of neoantigen vaccines in melanoma and glioblastoma and of adoptive transfer of neoantigen-specific T cells in epithelial tumors indicates that neoantigens are valid therapeutic targets. Improvements in sequencing tec...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Databases & Libraries | Genetics | Gleevec | Hematology | Laboratory Medicine | Leukemia | Molecular Biology